Exarmed Pharma Profile
Key Indicators
- Authorised Capital ₹ 13.50 Cr
as on 24-07-2024
- Paid Up Capital ₹ 13.50 Cr
as on 24-07-2024
- Company Age 5 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 109.07%
(FY 2023)
- Profit 358.57%
(FY 2023)
- Ebitda 358.57%
(FY 2023)
- Net Worth 0.27%
(FY 2023)
- Total Assets 1.21%
(FY 2023)
About Exarmed Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 13.50 Cr and a paid-up capital of Rs 13.50 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Exarmed Pharma Private Limited India is Ganamoor Reddy as COMPANY SECRETARY. Bala Thippabhotla, Jahnavi Puchakayala, and Vajrala Bhulakshmi serve as directors at the Company.
- CIN/LLPIN
U24110TG2019PTC129565
- Company No.
129565
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Jan 2019
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Gujvail, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Exarmed Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ganamoor Reddy  | Company Secretary | 01-Nov-2022 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Bala Thippabhotla | Director | 01-Jul-2019 | Current |
| Jahnavi Puchakayala | Director | 08-Jan-2019 | Current |
| Vajrala Bhulakshmi | Director | 08-Jan-2019 | Current |
Financial Performance and Corporate Structure Insights of Exarmed Pharma.
Exarmed Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 109.07% increase. The company also saw a substantial improvement in profitability, with a 358.57% increase in profit. The company's net worth moved up by a moderate rise of 0.27%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Exarmed Pharma?
In 2023, Exarmed Pharma had a promoter holding of 65.79% and a public holding of 34.21%. The company had 1 Associate company. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
13 years 3 months Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Exarmed Pharma?
Unlock and access historical data on people associated with Exarmed Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
As of Sep 08, 2021, Exarmed Pharma has raised a total of ₹ 13.49 Cr, with the most recent deal valued at ₹ 5 Cr. Access detailed insights into the company’s deals, including security allotments, mergers, acquisitions, and strategic partnerships that have shaped its growth.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
